Table: Santen Pharm -2017/18 group results (IFRS)
09/05/2018 07:00
May 9 (Reuters)-
Santen Pharmaceutical Co Ltd
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Mar 31, 2018 Mar 31, 2017 Mar 31, 2019 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 224.94 199.10 237.00
(+13.0 pct) (+1.9 pct) (+5.4 pct)
Operating 38.69 32.48 40.70
(+19.1 pct) (-59.5 pct) (+5.2 pct)
Pretax 39.26 30.06 41.30
(+30.6 pct) (-62.2 pct) (+5.2 pct)
Net 35.25 21.73
(+62.2 pct) (-59.3 pct)
EPS Basic 86.73 yen 52.96 yen 75.21 yen
EPS Diluted 86.42 yen 52.76 yen
Ann Div 26.00 yen 26.00 yen 26.00 yen
-Q2 Div 13.00 yen 13.00 yen 13.00 yen
-Q4 Div 13.00 yen 13.00 yen 13.00 yen
NOTE - Santen Pharmaceutical Co Ltd.
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T